GlassScriptPhysician profile
Vernon Reid Sutton
NPI 1104906445
$90,190.40
in general payments reported to CMS, 2019-2025
11 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,637 · 2020: $125 · 2021: $3,100 · 2022: $4,087 · 2023: $17K · 2024: $30K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $15K · Honoraria: $14K · Food and Beverage: $1,331 · Education: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $26,897.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,486.00 |
| Consulting Fee | $14,762.00 |
| Honoraria | $14,222.15 |
| Food and Beverage | $1,330.55 |
| Education | $543.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $40,691.26 | 2020-2025 | Voxzogo 1.2mg, Vimizim |
| Horizon Therapeutics Plc | $14,392.89 | 2019-2023 | Ravicti |
| Amgen INC. | $8,427.09 | 2024 | Ravicti |
| Ptc Therapeutics, INC. | $7,636.96 | 2019 | |
| Chiesi USA, INC. | $6,265.00 | 2022-2024 | Lamzede |
| Amicus Therapeutics, INC. | $4,526.55 | 2025 | Opfolda, Pombiliti |
| Immedica Pharma US, INC. | $4,000.00 | 2025 | |
| Applied Therapeutics, INC. | $2,530.71 | 2021-2022 | |
| Zevra Therapeutics INC | $1,647.15 | 2025 | Olpruva |
| Abbott Laboratories | $72.79 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.